CNSP - CNS Pharmaceuticals reports Q1 results

CNS Pharmaceuticals (CNSP): Q1 Net Loss of $3.6MCash and cash equivalents of $11M."The FDA has granted CNS Pharmaceuticals Orphan Drug Designation for Berubicin, which provides seven years of marketing exclusivity upon approval of an NDA.....In addition to the Company's global trial, sublicensee partner in Poland, WPD Pharmaceuticals, will initiate a Phase 2 multicenter clinical trial of Berubicin in GBM in the second half of 2021 and report an interim analysis of the first 18 patients by Q1-Q2 2022," company statement. In addition, CNS Pharmaceuticals continues to evaluate the use of its WP1244 drug technology in the treatment of brain cancers, pancreatic, ovarian, and lymphomas."Anticipated Upcoming Milestones: File IND in 2022." Press Release

For further details see:

CNS Pharmaceuticals reports Q1 results